Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Solara Active Pharma Sciences Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Founded in 2017, the company has quickly established itself as a key provider of high-quality products, catering to both domestic and international markets.
With a focus on innovation and sustainability, Solara offers a diverse range of APIs, particularly in the therapeutic areas of anti-infectives, cardiovascular, and central nervous system medications. The company’s commitment to quality and regulatory compliance has earned it a strong market position, with notable achievements in securing approvals from major global regulatory bodies. Solara's strategic operational regions extend across Asia, Europe, and the Americas, reinforcing its status as a trusted partner in the pharmaceutical supply chain.
-8 vs industry average
Solara Active Pharma Sciences Ltd’s score of 32 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Solara Active Pharma Sciences Ltd reported total emissions of approximately 41,178,000 kg CO2e, comprising 12,118,000 kg CO2e from Scope 1 and 28,660,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data.
Solara is committed to achieving net-zero emissions, as indicated by their near-term target status of "Committed." This commitment aligns with their operations in the Pharmaceuticals, Biotechnology, and Life Sciences sector, based in India.
Over the past few years, emissions have fluctuated, with 2024 emissions recorded at approximately 77,112,000 kg CO2e (33,489,000 kg CO2e from Scope 1 and 43,622,000 kg CO2e from Scope 2) and 2023 emissions at approximately 54,430,000 kg CO2e (11,168,000 kg CO2e from Scope 1 and 43,425,000 kg CO2e from Scope 2).
The company has not set specific reduction targets but remains focused on its long-term climate commitments. As of now, there are no emissions data cascaded from a parent or related organization.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Solara Active Pharma Sciences Ltd’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more